查看購物車
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
1982908

全球噬菌體療法市場規模、佔有率、趨勢和成長分析報告（2026-2034年）

Global Bacteriophage Therapy Market Size, Share, Trends & Growth Analysis Report 2026-2034
出版日期: | 出版商: Value Market Research | 英文 179 Pages | 商品交期: 最快1-2個工作天內

價格
簡介目錄

預計噬菌體療法市場將從 2025 年的 12.7 億美元成長到 2034 年的 18.4 億美元，2026 年至 2034 年的複合年成長率為 4.17%。

全球噬菌體療法市場正日益受到關注，被視為治療細菌感染的替代方法。噬菌體療法利用病毒特異性靶向並摧毀有害細菌，而不會影響有益微生物。這種治療方法正被探索作為解決日益嚴重的全球健康問題——抗生素抗藥性——的潛在方案。

多種因素共同推動了這一市場的成長。抗生素抗藥性感染疾病的增加迫使研究人員探索新的治療方法。噬菌體療法提供了一種標靶治療方案，與傳統抗生素相比，可能降低抗藥性產生的風險。此外，正在進行的研究和臨床試驗正在加深我們對噬菌體治療潛力的理解。

隨著人們對替代抗菌治療方法的興趣日益濃厚，噬菌體療法市場前景一片光明。生物技術和基因研究的進步有望提高噬菌體療法的療效和安全性。隨著醫學界不斷尋求應對抗生素抗藥性的解決方案，噬菌體療法有望成為重要的治療選擇。

目錄

第1章：引言

第2章執行摘要

第3章 市場變數、趨勢與框架

  • 市場譜系展望
  • 滲透率和成長前景分析
  • 價值鏈分析
  • 法律規範
    • 標準與合規性
    • 監管影響分析
  • 市場動態
    • 市場促進因素
    • 市場限制因素
    • 市場機遇
    • 市場挑戰
  • 波特五力分析
  • PESTLE分析

第4章：全球噬菌體療法市場：以標靶細菌分類

  • 市場分析、洞察與預測
  • 大腸桿菌
  • 金黃色葡萄球菌
  • 鏈球菌
  • 銅綠假單胞菌
  • 沙門氏菌
  • 其他

第5章 全球噬菌體療法市場：依適應症分類

  • 市場分析、洞察與預測
  • 尿道感染
  • 慢性中耳炎
  • 拔牙
  • 慢性潰瘍性大腸炎
  • 骨感染疾病
  • 傷口和皮膚感染疾病
  • 囊腫纖維化
  • 其他

第6章 全球噬菌體療法市場：依給藥途徑分類

  • 市場分析、洞察與預測
  • 口服
  • 局部行政部門
  • 腸外

第7章 全球噬菌體療法市場：依通路分類

  • 市場分析、洞察與預測
  • 醫院藥房
  • 零售藥房
  • 網路藥房

第8章 全球噬菌體療法市場：按地區分類

  • 區域分析
  • 北美市場分析、洞察與預測
    • 美國
    • 加拿大
    • 墨西哥
  • 歐洲市場分析、洞察與預測
    • 英國
    • 法國
    • 德國
    • 義大利
    • 俄羅斯
    • 其他歐洲國家
  • 亞太市場分析、洞察與預測
    • 印度
    • 日本
    • 韓國
    • 澳洲
    • 東南亞
    • 其他亞太國家
  • 拉丁美洲市場分析、洞察與預測
    • 巴西
    • 阿根廷
    • 秘魯
    • 智利
    • 其他拉丁美洲國家
  • 中東和非洲市場分析、洞察與預測
    • 沙烏地阿拉伯
    • UAE
    • 以色列
    • 南非
    • 其他中東和非洲國家

第9章 競爭情勢

  • 最新趨勢
  • 公司分類
  • 供應鏈和銷售管道合作夥伴（根據現有資訊）
  • 市場佔有率和市場定位分析（基於現有資訊）
  • 供應商情況（基於現有資訊）
  • 策略規劃

第10章：公司簡介

  • 主要公司的市佔率分析
  • 公司簡介
    • Armata Pharmaceuticals Inc
    • Adaptive Phage Therapeutics Inc
    • BiomX Inc
    • Intralytix Inc
    • Locus Biosciences Inc
    • ContraFect Corporation
    • Micreos BV
    • Enbiotix Inc
    • PhagePro Inc
    • Phagomed Biopharma GmbH
    • Eligo Bioscience SA
    • Pherecydes Pharma
    • Nextbiotics
    • InnoPhage Ltd
    • Phi Therapeutics
簡介目錄
Product Code: VMR11212974

The Bacteriophage Therapy Market size is expected to reach USD 1.84 Billion in 2034 from USD 1.27 Billion (2025) growing at a CAGR of 4.17% during 2026-2034.

The global bacteriophage therapy market is gaining attention as an alternative approach to treating bacterial infections. Bacteriophage therapy uses viruses that specifically target and destroy harmful bacteria without affecting beneficial microorganisms. This treatment method is being explored as a potential solution to antibiotic resistance, which has become a significant global health concern.

Several factors are contributing to the growth of this market. The rising prevalence of antibiotic-resistant infections is encouraging researchers to explore new treatment methods. Bacteriophage therapy offers a targeted approach that may reduce the risk of resistance compared to conventional antibiotics. Additionally, ongoing research and clinical trials are expanding knowledge about the therapeutic potential of bacteriophages.

The future outlook for the bacteriophage therapy market appears promising as interest in alternative antimicrobial treatments increases. Advances in biotechnology and genetic research are expected to improve the effectiveness and safety of bacteriophage therapies. As the medical community continues to search for solutions to antibiotic resistance, bacteriophage therapy may become an important treatment option.

Our reports are meticulously crafted to provide clients with comprehensive and actionable insights into various industries and markets. Each report encompasses several critical components to ensure a thorough understanding of the market landscape:

Market Overview: A detailed introduction to the market, including definitions, classifications, and an overview of the industry's current state.

Market Dynamics: In-depth analysis of key drivers, restraints, opportunities, and challenges influencing market growth. This section examines factors such as technological advancements, regulatory changes, and emerging trends.

Segmentation Analysis: Breakdown of the market into distinct segments based on criteria like product type, application, end-user, and geography. This analysis highlights the performance and potential of each segment.

Competitive Landscape: Comprehensive assessment of major market players, including their market share, product portfolio, strategic initiatives, and financial performance. This section provides insights into the competitive dynamics and key strategies adopted by leading companies.

Market Forecast: Projections of market size and growth trends over a specified period, based on historical data and current market conditions. This includes quantitative analyses and graphical representations to illustrate future market trajectories.

Regional Analysis: Evaluation of market performance across different geographical regions, identifying key markets and regional trends. This helps in understanding regional market dynamics and opportunities.

Emerging Trends and Opportunities: Identification of current and emerging market trends, technological innovations, and potential areas for investment. This section offers insights into future market developments and growth prospects.

MARKET SEGMENTATION

By Targeted Bacteria

  • Escherichia coli
  • Staphylococcus aureus
  • Streptococcus
  • Pseudomonas aeruginosa
  • Salmonella
  • Others

By Disease Indication

  • Urinary Tract Infections
  • Chronic Otitis
  • Dental Extraction
  • Chronic Ulcerative Colitis
  • Bone Infection
  • Wound and Skin Infections
  • Cystic Fibrosis
  • Others

By Route of Administration

  • Oral
  • Topical
  • Parenteral

By Distribution Channel

  • Hospital Pharmacies
  • Retail Pharmacies
  • Online Pharmacies

COMPANIES PROFILED

  • Armata Pharmaceuticals Inc, Adaptive Phage Therapeutics Inc, BiomX Inc, Intralytix Inc, Locus Biosciences Inc, ContraFect Corporation, Micreos BV, Enbiotix Inc, PhagePro Inc, Phagomed Biopharma GmbH, Eligo Bioscience SA, Pherecydes Pharma, Nextbiotics, InnoPhage Ltd, Phi Therapeutics
  • We can customise the report as per your requirements.

TABLE OF CONTENTS

Chapter 1. PREFACE

  • 1.1. Market Segmentation & Scope
  • 1.2. Market Definition
  • 1.3. Information Procurement
    • 1.3.1 Information Analysis
    • 1.3.2 Market Formulation & Data Visualization
    • 1.3.3 Data Validation & Publishing
  • 1.4. Research Scope and Assumptions
    • 1.4.1 List of Data Sources

Chapter 2. EXECUTIVE SUMMARY

  • 2.1. Market Snapshot
  • 2.2. Segmental Outlook
  • 2.3. Competitive Outlook

Chapter 3. MARKET VARIABLES, TRENDS, FRAMEWORK

  • 3.1. Market Lineage Outlook
  • 3.2. Penetration & Growth Prospect Mapping
  • 3.3. Value Chain Analysis
  • 3.4. Regulatory Framework
    • 3.4.1 Standards & Compliance
    • 3.4.2 Regulatory Impact Analysis
  • 3.5. Market Dynamics
    • 3.5.1 Market Drivers
    • 3.5.2 Market Restraints
    • 3.5.3 Market Opportunities
    • 3.5.4 Market Challenges
  • 3.6. Porter's Five Forces Analysis
  • 3.7. PESTLE Analysis

Chapter 4. GLOBAL BACTERIOPHAGE THERAPY MARKET: BY TARGETED BACTERIA 2022-2034 (USD MN)

  • 4.1. Market Analysis, Insights and Forecast Targeted Bacteria
  • 4.2. Escherichia coli Estimates and Forecasts By Regions 2022-2034 (USD MN)
  • 4.3. Staphylococcus aureus Estimates and Forecasts By Regions 2022-2034 (USD MN)
  • 4.4. Streptococcus Estimates and Forecasts By Regions 2022-2034 (USD MN)
  • 4.5. Pseudomonas aeruginosa Estimates and Forecasts By Regions 2022-2034 (USD MN)
  • 4.6. Salmonella Estimates and Forecasts By Regions 2022-2034 (USD MN)
  • 4.7. Others Estimates and Forecasts By Regions 2022-2034 (USD MN)

Chapter 5. GLOBAL BACTERIOPHAGE THERAPY MARKET: BY DISEASE INDICATION 2022-2034 (USD MN)

  • 5.1. Market Analysis, Insights and Forecast Disease Indication
  • 5.2. Urinary Tract Infections Estimates and Forecasts By Regions 2022-2034 (USD MN)
  • 5.3. Chronic Otitis Estimates and Forecasts By Regions 2022-2034 (USD MN)
  • 5.4. Dental Extraction Estimates and Forecasts By Regions 2022-2034 (USD MN)
  • 5.5. Chronic Ulcerative Colitis Estimates and Forecasts By Regions 2022-2034 (USD MN)
  • 5.6. Bone Infection Estimates and Forecasts By Regions 2022-2034 (USD MN)
  • 5.7. Wound and Skin Infections Estimates and Forecasts By Regions 2022-2034 (USD MN)
  • 5.8. Cystic Fibrosis Estimates and Forecasts By Regions 2022-2034 (USD MN)
  • 5.9. Others Estimates and Forecasts By Regions 2022-2034 (USD MN)

Chapter 6. GLOBAL BACTERIOPHAGE THERAPY MARKET: BY ROUTE OF ADMINISTRATION 2022-2034 (USD MN)

  • 6.1. Market Analysis, Insights and Forecast Route Of Administration
  • 6.2. Oral Estimates and Forecasts By Regions 2022-2034 (USD MN)
  • 6.3. Topical Estimates and Forecasts By Regions 2022-2034 (USD MN)
  • 6.4. Parenteral Estimates and Forecasts By Regions 2022-2034 (USD MN)

Chapter 7. GLOBAL BACTERIOPHAGE THERAPY MARKET: BY DISTRIBUTION CHANNEL 2022-2034 (USD MN)

  • 7.1. Market Analysis, Insights and Forecast Distribution Channel
  • 7.2. Hospital Pharmacies Estimates and Forecasts By Regions 2022-2034 (USD MN)
  • 7.3. Retail Pharmacies Estimates and Forecasts By Regions 2022-2034 (USD MN)
  • 7.4. Online Pharmacies Estimates and Forecasts By Regions 2022-2034 (USD MN)

Chapter 8. GLOBAL BACTERIOPHAGE THERAPY MARKET: BY REGION 2022-2034(USD MN)

  • 8.1. Regional Outlook
  • 8.2. North America Market Analysis, Insights and Forecast, 2022-2034 (USD MN)
    • 8.2.1 By Targeted Bacteria
    • 8.2.2 By Disease Indication
    • 8.2.3 By Route Of Administration
    • 8.2.4 By Distribution Channel
    • 8.2.5 United States
    • 8.2.6 Canada
    • 8.2.7 Mexico
  • 8.3. Europe Market Analysis, Insights and Forecast, 2022-2034 (USD MN)
    • 8.3.1 By Targeted Bacteria
    • 8.3.2 By Disease Indication
    • 8.3.3 By Route Of Administration
    • 8.3.4 By Distribution Channel
    • 8.3.5 United Kingdom
    • 8.3.6 France
    • 8.3.7 Germany
    • 8.3.8 Italy
    • 8.3.9 Russia
    • 8.3.10 Rest Of Europe
  • 8.4. Asia-Pacific Market Analysis, Insights and Forecast, 2022-2034 (USD MN)
    • 8.4.1 By Targeted Bacteria
    • 8.4.2 By Disease Indication
    • 8.4.3 By Route Of Administration
    • 8.4.4 By Distribution Channel
    • 8.4.5 India
    • 8.4.6 Japan
    • 8.4.7 South Korea
    • 8.4.8 Australia
    • 8.4.9 South East Asia
    • 8.4.10 Rest Of Asia Pacific
  • 8.5. Latin America Market Analysis, Insights and Forecast, 2022-2034 (USD MN)
    • 8.5.1 By Targeted Bacteria
    • 8.5.2 By Disease Indication
    • 8.5.3 By Route Of Administration
    • 8.5.4 By Distribution Channel
    • 8.5.5 Brazil
    • 8.5.6 Argentina
    • 8.5.7 Peru
    • 8.5.8 Chile
    • 8.5.9 South East Asia
    • 8.5.10 Rest of Latin America
  • 8.6. Middle East & Africa Market Analysis, Insights and Forecast, 2022-2034 (USD MN)
    • 8.6.1 By Targeted Bacteria
    • 8.6.2 By Disease Indication
    • 8.6.3 By Route Of Administration
    • 8.6.4 By Distribution Channel
    • 8.6.5 Saudi Arabia
    • 8.6.6 UAE
    • 8.6.7 Israel
    • 8.6.8 South Africa
    • 8.6.9 Rest of the Middle East And Africa

Chapter 9. COMPETITIVE LANDSCAPE

  • 9.1. Recent Developments
  • 9.2. Company Categorization
  • 9.3. Supply Chain & Channel Partners (based on availability)
  • 9.4. Market Share & Positioning Analysis (based on availability)
  • 9.5. Vendor Landscape (based on availability)
  • 9.6. Strategy Mapping

Chapter 10. COMPANY PROFILES OF GLOBAL BACTERIOPHAGE THERAPY INDUSTRY

  • 10.1. Top Companies Market Share Analysis
  • 10.2. Company Profiles
    • 10.2.1 Armata Pharmaceuticals Inc
    • 10.2.2 Adaptive Phage Therapeutics Inc
    • 10.2.3 BiomX Inc
    • 10.2.4 Intralytix Inc
    • 10.2.5 Locus Biosciences Inc
    • 10.2.6 ContraFect Corporation
    • 10.2.7 Micreos B.V
    • 10.2.8 Enbiotix Inc
    • 10.2.9 PhagePro Inc
    • 10.2.10 Phagomed Biopharma GmbH
    • 10.2.11 Eligo Bioscience SA
    • 10.2.12 Pherecydes Pharma
    • 10.2.13 Nextbiotics
    • 10.2.14 InnoPhage Ltd
    • 10.2.15 Phi Therapeutics